Rösch AG Medizintechnik
Rösch AG Medizintechnik english

Rösch AG: restructuring measures as part of strategic focussing Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rösch AG: restructuring measures as part of strategic focussing Budget figures for the 2001/2002, 2002/2003, 2003/2004 financial years Rösch AG announces the following measures as part of strategic focussing on the business area of needle-free injection and monitoring systems:Rösch AG is discontinuing its activities in the Dental area. The 100% subsidiaries mdc GmbH and mdc KG, on which the dental sector concentrated, will discontinue its business activities by July 31, 02, at the latest. This will result in valuation adjustments to the group result of EUR 5.5 million for write-downs from goodwill and provisions as well as other restructuring expenditure flowing into the group result in the 01/02 financial year. All identifiable risks arising from the restructuring measures have thus been taken into account. Furthermore, the Management Board has resolved to discontinue the business activities of the 100 % subsidiary Acanthos GmbH (sales with nursing services) with immediate effect. The transfer of expertise to Rösch AG is complete. The important customer relationship in the Nursing Services area as a service provider to the health insurance companies is controlled centrally from Berlin by Rösch AG. Due to the discontinuation of the dental sector the number of employees will drop to 49. The savings thus initiated will allow for a positive budget result for Rösch AG in the second quarter of the 02/03 financial year. The participation in Ritter Concept GmbH (44 %) will continue as a purely financial participation. It generated a slightly positive result in the period from mid-September to December 31, 01 and sales of approx. EUR 2 million. Rösch AG is thus underlining its focus on the needle-free technologies area and the resulting orientation as a research, development and co-operation partner for the pharmaceutical industry. Rösch will announce its half-yearly figures for the period August 1, 01 to January 31, 02 at the end of March 02.Taking into consideration this consistent re-orientation of the company, the following budget figures for the Rösch Group (financial year from August 1 to July 31) are planned: 01/02: sales EUR 4.4 mill, EBIT EUR -14.1 mill (incl. restructuring expenditure) 02/03: sales EUR 12.6 mill, EBIT EUR -1.1 mill 03/04: sales EUR 20.0 mill, EBIT EUR 4.4 mill Further information: Rösch AG, Tel.: +49 (30) 667915930 end of ad-hoc-announcement (c)DGAP 06.02.2002 ——————————————————————————– WKN: 529 140; ISIN: DE0005291405; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 060838 Feb 02